Revolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) EV/FCF
As of 5 November 2026, Revolution Medicines, Inc. (RVMD) trades at a EV/FCF of −25.0×. Over the past ten years it has ranged from −35.5× (August 2026) to 1.5× (March 2020); the current reading is higher than 10% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2023 | −6.1× | — |
| FY2022 | −5.4× | — |
| FY2021 | −8.6× | — |
| FY2020 | −17.1× | — |
| FY2019 | 0.9× | 0.00% |
| FY2018 | 0.9× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −28.8× | — |
| Dec 2023 | −6.1× | — |
| Jun 2023 | −8.0× | — |
| Mar 2023 | −5.0× | — |
| 16 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| INSM Insmed, Inc. compare | −37.2× |
| ROIV Roivant Sciences Ltd. compare | −28.1× |
| RVMD Revolution Medicines, Inc. | −25.0× |
| BNTX BioNTech SE Sponsored ADR compare | −9.6× |
| GMAB Genmab A/S Sponsored ADR compare | −5.7× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 27.1× |
| RPRX Royalty Pharma PLC compare | 29.5× |
| INCY Incyte Corporation compare | 29.7× |
| ARGX argenex SE compare | 38.4× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on RVMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement